Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Revolution Medicines (RVMD) over the last 6 years, with Q3 2025 value amounting to 2654.81%.

  • Revolution Medicines' EBITDA Margin changed N/A to 2654.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 8802.29%, marking a year-over-year increase of 907749300.0%. This contributed to the annual value of 3748.21% for FY2023, which is 30412900.0% down from last year.
  • Latest data reveals that Revolution Medicines reported EBITDA Margin of 2654.81% as of Q3 2025.
  • Revolution Medicines' EBITDA Margin's 5-year high stood at 2654.81% during Q3 2025, with a 5-year trough of 21579.78% in Q4 2023.
  • For the 4-year period, Revolution Medicines' EBITDA Margin averaged around 2769.96%, with its median value being 722.9% (2022).
  • Per our database at Business Quant, Revolution Medicines' EBITDA Margin surged by 25481300bps in 2022 and then plummeted by -211772600bps in 2023.
  • Quarter analysis of 4 years shows Revolution Medicines' EBITDA Margin stood at 559.33% in 2021, then rose by 28bps to 402.52% in 2022, then plummeted by -5261bps to 21579.78% in 2023, then surged by 112bps to 2654.81% in 2025.
  • Its EBITDA Margin was 2654.81% in Q3 2025, compared to 21579.78% in Q4 2023 and 2845.11% in Q2 2023.